U.S. health regulator approves Teva's migraine drug

The world's largest generic drugmaker had hoped to receive approval for the injectable drug, fremanezumab, by June.

The world's largest generic drugmaker had hoped to receive approval for the injectable drug, fremanezumab, by June. Its release was delayed due to U.S. regulatory concerns about the manufacturing process at the South Korean plant of its development partner Celltrion.

Around 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, making for a large market that has attracted several drugmakers.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)